A Phase 1 interventional study of DW4421S-T0 and DW4421S-T2 in Healthy Adult Volunteers, sponsored by Daewon Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Daewon Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Multiple Ascending Dose of DW4421, phase I
Daewon Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DW4421S-T0, 1 tablet will be orally administered in BID for 7days
Drug: DW4421S-T0
DW4421S-T0, 1 tablet will be orally administered in QD for 7days
Drug: DW4421S-T0
DW4421S-T2, 1 tablet will be orally administered in QD for 7days
Drug: DW4421S-T2
DW4421S-T1, 1 tablet will be orally administered in QD for 7days
Drug: DW4421S-T1
DW4421S-T3, 1 tablet will be orally administered in QD for 7days
Drug: DW4421S-T3
DW4421S, 1 tablet will be orally administered in QD for 7days
Drug: DW4421S
DW4421-3, 1 tablet will be orally administered in QD for 7days
Drug: DW4421-3
DW4421 5mg
DW4421 15mg
DW4421 20mg
DW4421 30mg
DW4421 40mg
Zastaprazan 20mg
AUCτ,ss, Area under the drug concentration-time curve of DW4421 following multiple oral administration
Assessment of pharmacokinetic parameters of DW4421 after multiple oral administration
Time frame: Day 7
Cmax of DW4421 following multiple oral administration
Assessment of pharmacokinetic parameters of DW4421 after multiple oral administration
Time frame: Day 7
Plan to share: Undecided — A decision on whether to share individual participant data has not yet been made. We plan to evaluate the feasibility of data sharing after the study is completed and the primary results are published
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: DW4421S
Daewon Pharmaceutical Co., Ltd. →